Original Article: https://doi.org/10.1056/nejmoa2024816
- Patients with chronic kidney disease have a high risk of unfavorable kidney and cardiovascular consequences.
- Researchers do not know the effect of dapagliflozin in patients (with or without type 2 diabetes) with chronic kidney disease.
- Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2.
- The study involves 4304 participants with glomerular filtration rate and urinary albumin-to-creatinine ratio assessed.
- The participants were randomly assigned to receive dapagliflozin or placebo.
- The primary outcome was a combination of a sustained reduction in the estimated glomerular filtration rate of at least 50 percent, end-stage kidney disease, or death from renal or cardiovascular disease.
- The trial was stopped because of efficacy.
- Primary outcome event occurred in 197 of 2152 participants in the dapagliflozin group.
- Primary outcome event occurred in 312 of 2152 participants in the placebo group.
- Death occurred in 101 participants in the dapagliflozin group.
- Death occurred in 146 participants in the placebo group.
- The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without type 2 diabetes.
- The study concluded that dapagliflozin is correlated with lower risk of a composite of a sustained decline in the estimated glomerular filtration rate of at least 50 percent, end-stage kidney disease, or death from renal or cardiovascular causes.